Is AbCellera Biologics Inc. (ABCL) a Buy, Sell, or Hold?
NASDAQ : ABCL
AbCellera Biologics Inc.
$5.25 USD
-$0.06 (-1.13%)
- Volume
- 4.13M
- Average Volume
- 7.99M
- Market Capitalization
- $1.6B
- P/E Ratio
- -10.94
- Dividend Yield
- 0.00%
- Price Target
- $7.50
- Year High
- $8.44
- Year Low
- $2.75
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $14.05
Company Overview
NASDAQ
Carl Hansen
Biotechnology
Healthcare
ABCL
562
CA
USD
Liquidity Metrics
0.15
14.05
13.89
1.63
0.00
Sales & Valuation
$75.13M
20.24
1.70
-8.47
-0.62
Profitability
-$0.49
-$146.41M
-181.75%
-219.86%
-14.86%
-11.01%
P/E Metrics
-10.94
-0.70
-0.70
Analyst Price Target & Rating
$7.50
$8.00
$7.00
2/5
11 Analysts
-30.00%
Financial Health Scores
2.71
2/9
$617.3M
$1.31B
$369.03M
-$188.48M
Key Metrics (TTM)
$1.68B
21.27
-10.69
14.05
-14.86%
-13.84%
-8.95%
-11.67%
248 days
Company Executives
| Name | Title |
|---|---|
| Tiffany Chiu | Vice President of Communications |
| Caitlin Webster CIPD | Director of Talent Development |
| Carl Hansen | Chief Executive Officer, President & Chairperson |
| Veronique Lecault | Chief Technology Officer & Director |
| Marcie Thiessen | Senior Director of Finance & Accounting |
| Andrew Knowles | Vice President of Operations |
| Martin Hogan | Senior Director of Strategic Finance & IR |
| Murray McCutcheon | Senior Vice President of Partnering |
| Andrew Booth | Chief Financial Officer |
| Tryn T. Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer |
Poll Results
No votes yet today — be the first to share your view!
About AbCellera Biologics Inc. (NASDAQ:ABCL) Stock
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada. ...
Playing The Biotech Breakout With Insiders
2026-07-23 15:15:20
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
2026-07-23 09:05:00
/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-07 16:05:00
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026.
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice
2026-07-07 13:01:15
Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
2026-07-06 09:00:00
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Lynn Seely to its Board of Directors.
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
2026-07-03 10:41:15
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
2026-06-25 09:46:08
ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
2026-06-18 11:31:04
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Frequently Asked Questions
-
What is the current AbCellera Biologics Inc. (ABCL) stock price?
-
AbCellera Biologics Inc.(NASDAQ:ABCL) stock price is $5.25 in the last trading session. During the trading session, ABCL stock reached the peak price of $8.44 while $2.745 was the lowest point it dropped to. The percentage change in ABCL stock occurred in the recent session was --1.13% while the dollar amount for the price change in ABCL stock was -$0.06.
-
ABCL's industry and sector of operation?
-
The NASDAQ listed ABCL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ABCL?
-
Tiffany Chiu | Vice President of Communications
Caitlin Webster CIPD | Director of Talent Development
Carl Hansen | Chief Executive Officer, President & Chairperson
Veronique Lecault | Chief Technology Officer & Director
Marcie Thiessen | Senior Director of Finance & Accounting -
How many employees does ABCL have?
-
Number of ABCL employees currently stands at 562. ABCL operates from 150 W 4th Ave, Vancouver, BC V5Y 0A1, CA.
-
Link for ABCL official website?
-
Official Website of ABCL is: https://www.abcellera.com
-
How do I contact ABCL?
-
ABCL could be contacted at phone #604 559 9005 and can also be accessed through its website. ABCL operates from 150 W 4th Ave, Vancouver, BC V5Y 0A1, CA.
-
How many shares of ABCL are traded daily?
-
The average number of ABCL shares traded daily for last 3 months was 7.99M.
-
What is the market cap of ABCL currently?
-
The market value of ABCL currently stands at $1.6B with its latest stock price at $5.25